Histone deacetylases: Unique players in shaping the epigenetic histone code

Annals of the New York Academy of Sciences

Volumn 983, Issue , 2003, Pages 84-100

  Thiagalingam, Sam ^a   Cheng, Kuang Hung ^a   Lee, Hyunjoo J ^a   Mineva, Nora ^a   Thiagalingam, Arunthathi ^b   Ponte, Jose F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Active histone code (AHC); Cancer therapy; Histone code; Histone deacetylase inhibitor (HDACi); Histone deacetylases (HDAC); Silenced histone code (SHC)

Indexed keywords

4 (METHYLNITROSOAMINO) 1 (3 PYRIDYL) 1 BUTANONE; APICIDIN; AZELOIC BISHYDROXAMATE; BUTYRIC ACID; ENZYME INHIBITOR; FR 901228; FUNGAL PROTEIN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LYSINE; MS 27275; OXAMFLATIN; SILENT INFORMATION REGULATOR PROTEIN 2; SUBEROYLANILIDE HYDROXYAMIC ACID; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

CANCER; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; GENETIC CODE; GENOME; HUMAN; NONHUMAN; PROTEIN LOCALIZATION; RNA TRANSLATION; SIDE EFFECT; YEAST;

EID: 0344407016     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb05964.x     Document Type: Conference Paper

References (139)

1. STRAHL, B.D. & C.D. ALLIS. 2000. The language of covalent histone modifications. Nature 403: 41-45.
2. RICE, J.C. & C.D. ALLIS. 2001. Code of silence. Nature 414: 258-261.
3. Li, E. 2002. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3: 662-673.
4. THIAGALINGAM, S. et al. 2002. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14: 65-72.
5. LUGER, K. & T.J. RICHMOND. 1998. The histone tails of the nucleosome. Curr. Opin. Genet. Dev. 8: 140-146.
6. LUGER, K. et al. 1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260.
7. JENUWEIN, T. & C.D. ALLIS. 2001. Translating the histone code. Science 293: 1074-1080.
8. ALLFREY, V.G. 1966. Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc. Can. Cancer Conf. 6: 313-335.
9. ITAZAKI, H. et al. 1990. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot. (Tokyo) 43: 1524-1532.
10. KIJIMA, M. et al. 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268: 22429-22435.
11. TAUNTON, J., C.A. HASSIG & S.L. SCHREIBER. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408-411.
12. ZHANG, C.L. et al. 2002. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-488.
13. SUN, J.M. et al. 2002. The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J. Biol. Chem. 277: 35783-35786.
14. WON, J., J. YIM & T.K. KIM. 2002. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J. Biol. Chem. 277: 38230-38238.
15. YU, Z., W. ZHANG & B.C. KONE. 2002. Histone deacetylases augment cytokine induction of the iNOS gene. J. Am. Soc. Nephrol. 13: 2009-2017.
16. ZHANG, Y. & M.L. DUFAU. 2002. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J. Biol. Chem. 277: 33431-33438.
17. OZAWA, Y. et al. 2001. Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood 98: 2116-2123.
18. KIM, Y.B. et al. 2000. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiot. (Tokyo) 53: 1191-1200.
19. MILUTINOVIC, S., Q. ZHUANG & M. SZYF. 2002. Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification. J. Biol. Chem. 277: 20974-20978.
20. Wang, C. et al. 2001. Histone acetylation and the cell-cycle in cancer. Front. Biosci. 6: D610-629.
21. ZHANG, Z.K. et al. 2002. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol. Cell. Biol. 22: 5975-5988.
22. BESTOR, T.H. 1998. Gene silencing. Methylation meets acetylation. Nature 393: 311-312.
23. KIM, J. et al. 1999. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 10: 345-355.
24. ZHOU, X. et al. 2000. Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc. Natl. Acad. Sci. USA 97: 1056-1061.
25. XIE, A.Y. & W.R. FOLK. 2002. Inhibition of polyomavirus ori-dependent DNA replication by mSin3B. J. Virol. 76: 11809-11818.
26. GRUFFAT, H., E. MANET & A. SERGEANT. 2002. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF 1 links latency and chromatin remodeling. EMBO Rep. 3: 141-146.
27. LAI, A. et al. 2001. RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. Mol. Cell. Biol. 21: 2918-2932.
28. JOHNSON, C.A. et al. 2001. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J. Biol. Chem. 276: 4539-4542.
29. JUAN, L.J. et al. 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275: 20436-20443.
30. Luo, J. et al. 2000. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
31. Luo, J. et al. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
32. CHEN, Z. et al. 2002. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 188: 127-140.
33. ROBYR, D. et al. 2002. Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell 109: 437-446.
34. YANG, W.M. et al. 1997. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 272: 28001-28007.
35. DANGOND, F. et al. 1998. Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem. Biophys. Res. Commun. 242: 648-652.
36. EMILIANI, S. et al. 1998. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. USA 95: 2795-2800.
37. Hu, E. et al. 2000. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 275: 15254-15264.
38. BUGGY, J.J. et al. 2000. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem. J. 350 Pt 1: 199-205.
39. VAN DEN WYNGAERT, I. et al. 2000. Cloning and characterization of human histone deacetylase 8. FEBS Lett. 478: 77-83.
40. DANGOND, F. & S.R. GULLANS. 1998. Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem. Biophys. Res. Commun. 247: 833-837.
41. KAO, H.Y. et al. 1998. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 12: 2269-2277.
42. VERDEL, A. et al. 2000. Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr. Biol. 10: 747-749.
43. CRESS, W.D. & E. SETO. 2000. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184: 1-16.
44. ZHANG, Y. et al. 1999. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13: 1924-1935.
45. KNOEPFLER, P.S. & R.N. EISENMAN. 1999. Sin meets NuRD and other tails of repression. Cell 99: 447-450.
46. YOU, A. et al. 2001. CoREST is an integral component of the CoREST - human histone deacetylase complex. Proc. Natl. Acad. Sci. USA 98: 1454-1458.
47. LAI, A. et al. 1999. RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins. Mol. Cell. Biol. 19: 6632-6641.
48. ROBERTSON, K.D. et al. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25: 338-342.
49. ROUNTREE, M.R., K.E. BACHMAN & S.B. BAYLIN. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25: 269-277.
50. WOTTON, D. et al. 1999. A Smad transcriptional corepressor. Cell 97: 29-39.
51. ITO, K., P.J. BARNES & I.M. ADCOCK. 2000. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 20: 6891-6903.
52. CHOI, H.S. et al. 2002. Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem. Biophys. Res. Commun. 296: 1005-1012.
53. WEN, Y.D. et al. 2000. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA 97: 7202-7207.
54. LI, J. et al. 2000. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19: 4342-4350.
55. ZHANG, J. et al. 2002. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol. Cell. 9: 611-623.
56. GALASINSKI, S.C. et al. 2002. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J. Biol. Chem. 277: 19618-19626.
57. TSAI, S.C. & E. SETO. 2002. Regulation of histone deacetylase 2 by protein kinase CK2. J. Biol. Chem. 277: 31826-31833.
58. DAVID, G., M.A. NEPTUNE & R.A. DEPINHO. 2002. SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J. Biol. Chem. 277: 23658-23663.
59. GROZINGER, C.M., C.A. HASSIG & S.L. SCHREIBER. 1999. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. USA 96: 4868-4873.
60. FISCHLE, W. et al. 1999. A new family of human historic deacetylases related to Saccharomyces cerevisiae HDA1p. J. Biol. Chem. 274: 11713-11720.
61. ZHOU, X. et al. 2001. Cloning and characterization of a historic deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA 98: 10572-10577.
62. FISCHER, D.D. et al. 2002. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. 277: 6656-6666.
63. HUANG, E.Y. et al. 2000. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 14: 45-54.
64. GROZINGER, C.M. & S.L. SCHREIBER. 2000. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. USA 97: 7835-7840.
65. BANNISTER, A.J. et al. 2000. Acetylation of importin-alpha nuclear import factors by CBP/p300. Curr. Biol. 10: 467-470.
66. FISCHLE, W. et al. 2002. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell. 9: 45-57.
67. LEMERCIER, C. et al. 2000. mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. J. Biol. Chem. 275: 15594-15599.
68. MISKA, E.A. et al. 1999. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 18: 5099-5107.
69. ZHANG, C.L. et al. 2001. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J. Biol. Chem. 276: 35-39.
70. GAO, L. et al. 2002. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277: 25748-25755.
71. HUBBERT, C. et al. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
72. GUARENTE, L. 2000. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14: 1021-1026.
73. FRYE, R.A. 1999. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260: 273-279.
74. BRACHMANN, C.B. et al. 1995. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 9: 2888-2902.
75. IMAI, S. et al. 2000. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
76. AFSHAR, G. & J. P. MURNANE. 1999. Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene 234: 161-168.
77. KUZMICHEV, A. et al. 2002. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol. Cell. Biol. 22: 835-848.
78. LANGLEY, E. et al. 2002. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21: 2383-2396.
79. VAZIRI, H. et al. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
80. BANNISTER, A.J. et al. 2001. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120-124.
81. SCHNEIDER, R., A.J. BANNISTER & T. KOUZARIDES. 2002. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem. Sci. 27: 396-402.
82. BOEKE, J. et al. 2000. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J. Biol. Chem. 275: 34963-34967.
83. LACHNER, M. et al. 2001. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410: 116-120.
84. NEELY, K. & J. WORKMAN. 2002. The complexity of chromatin remodeling and its links to cancer. Biochim. Biophys. Acta 1603: 19.
85. STROBECK, M.W. et al. 2000. BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl. Acad. Sci. USA 97: 7748-7753.
86. TROUCHE, D. et al. 1997. RB and hbrm cooperate to repress the activation functions of E2F1. Proc. Natl. Acad. Sci. USA 94: 11268-11273.
87. ZHANG, H.S. et al. 2000. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101: 79-89.
88. STROBER, B.E. et al. 1996. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol. Cell. Biol. 16: 1576-1583.
89. DUNAIEF, J.L. et al. 1994. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79: 119-130.
90. NG, H.H. et al. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23: 58-61.
91. FUKS, F. et al. 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20: 2536-44.
92. DEPLUS, R. et al. 2002. Dnmt3L is a transcriptional repressor that recruits histone deacetylase. Nucleic Acids Res. 30: 3831-3838.
93. MARKS, P.A., V.M. RICHON & R.A. RIFKIND. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92: 1210-1216.
94. JUNG, M. 2001. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8: 1505-1511.
95. CHOPIN, V. et al. 2002. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br. J. Pharmacol. 135: 79-86.
96. SAWA, H. et al. 2001. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bc1-2-related protein Bad. Brain Tumor Pathol. 18: 109-114.
97. HEROLD, C. et al. 2002. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36: 233-240.
98. COHEN, L.A. et al. 1999. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 19: 4999-5005.
99. COHEN, L.A. et al. 2002. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. 22: 1497-1504.
100. RICHON, V.M. et al. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95: 3003-3007.
101. KIM, Y.B. et al. 1999. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461-2470.
102. YOSHIDA, M. & S. HORINOUCHI. 1999. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann. N.Y. Acad. Sci. 886: 23-36.
103. KIM, M.S. et al. 2000. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157: 23-30.
104. HAN, J.W. et al. 2000. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cipl and gelsolin. Cancer Res. 60: 6068-6074.
105. NAKAJIMA, H. et al. 1998. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241: 126-133.
106. JABOIN, J. et al. 2002. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62: 6108-6115.
107. SAITO, A. et al. 1999. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96: 4592-4597.
108. MCCAFFREY, P.G. et al. 1997. Induction of gamma-globin by histone deacetylase inhibitors. Blood 90: 2075-2083.
109. RANSOM, R.F. & J.D. WALTON. 1997. Histone hyperacetylation in maize in response to treatment with HC-toxin or infection by the filamentous fungus Cochliobolus carbonum. Plant Physiol. 115: 1021-1027.
110. DEMARY, K., L. WONG & R.A. SPANJAARD. 2001. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett. 163: 103-107.
111. VIGUSHIN, D.M. et al. 2001. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7: 971-976.
112. RASHID, S.F. et al. 2001. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20: 1860-1872.
113. HOU, M. et al. 2002. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp. Cell. Res. 274: 25-34.
114. VAN LINT, C., S. EMILIANI & E. VERDIN. 1996. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5: 245-253.
115. BUTLER, L.M. et al. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99: 11700-11705.
116. MUNSTER, P.N. et al. 2001. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61: 8492-8497.
117. AMIN, H.M., S. SAEED & S. ALKAN. 2001. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br. J. Haematol. 115: 287-297.
118. DEROANNE, C.F. et al. 2002. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436.
119. YOSHIDA, M. et al. 2001. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48 Suppl. 1: S20-26.
120. KWON, H.J., et al. 2002. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer. 97: 290-296.
121. LEE, B.I. et al. 2001. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res. 61: 931-934.
122. COTE, S. et al. 2002. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood. 100: 2586-2596.
123. FERRARA, F.F. et al. 2001. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61: 2-7.
124. HE, L.Z. et al. 2001. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108: 1321-1330.
125. KITAMURA, K. et al. 2000. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 108: 696-702.
126. LIN, R.J. et al. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814.
127. MINUCCI, S. et al. 2001. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20: 3110-3115.
128. PANDOLFI, P.P. 2001. Transcription therapy for cancer. Oncogene 20: 3116-3127.
129. FINNIN, M.S. et al. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
130. GROZINGER, C.M. & S.L. SCHREIBER. 2002. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9: 3-16.
131. RANDHAWA, G.S. et al. 1998. Identification and mapping of human histone acetylation modifier gene homologues. Genomics 51: 262-269.
132. FURUKAWA, Y. et al. 1996. Isolation and mapping of a human gene (RPD3L1) that is homologous to RPD3, a transcription factor in Saccharomyces cerevisiae. Cytogenet. Cell Genet. 73: 130-133.
133. BETZ, R. et al. 1998. Human histone deacetylase 2, HDAC2 (Human RPD3), is localized to 6q21 by radiation hybrid mapping. Genomics 52: 245-246.
134. WANG, A.H. et al. 1999. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol. 19: 7816-7827.
135. TONG, J.J. et al. 2002. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30: 1114-1123.
136. GUARDIOLA, A.R. & T.P. YAO. 2002. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 277: 3350-3356.
137. KAO, H.Y. et al. 2002. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 277: 187-193.
138. FRYE, R.A. 2000. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273: 793-798.
139. NEWMARK, H.L. & C.W. YOUNG. 1995. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell. Biochem. Suppl. 22: 247-253.